Narrative Update • Jun 26
Have your own idea? Try our Stock Screener
U.K. (FTSE) Clinical Research and Equipment Industry Analysis
UpdatedJun 27, 2026
DataAggregated Company Financials
Companies7
- 7D4.5%
- 3M7.6%
- 1Y-8.1%
- YTDn/a
In the last week, the Clinical Research and Equipment industry is up 4.5%, with Oxford Nanopore Technologies up 6.5%. Meanwhile, hVIVO actually underperformed within the industry, shrinking 12% in the last week. However, the industry is down 8.1% over the past year. As for the next few years, earnings are expected to grow by 57% per annum.
Industry Valuation and Performance
Has the U.K. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 27 Jun 2026 | UK£1.4b | UK£323.0m | -UK£166,018,254.00 | 1265.7x | -8.5x | 4.4x |
| Mon, 25 May 2026 | UK£1.5b | UK£318.9m | -UK£167,635,254.00 | n/a | -9x | 4.7x |
| Wed, 22 Apr 2026 | UK£1.4b | UK£318.2m | -UK£167,469,254.00 | n/a | -8.6x | 4.5x |
| Fri, 20 Mar 2026 | UK£1.4b | UK£324.0m | -UK£161,423,254.00 | 9.5x | -8.5x | 4.2x |
| Sun, 15 Feb 2026 | UK£1.6b | UK£304.6m | -UK£159,441,254.00 | 10.9x | -9.8x | 5.1x |
| Tue, 13 Jan 2026 | UK£1.7b | UK£304.6m | -UK£159,441,254.00 | 8x | -10.7x | 5.6x |
| Thu, 11 Dec 2025 | UK£1.5b | UK£304.4m | -UK£160,881,254.00 | 5.9x | -9.1x | 4.8x |
| Sat, 08 Nov 2025 | UK£1.6b | UK£304.3m | -UK£163,156,254.00 | 8.2x | -9.6x | 5.2x |
| Mon, 06 Oct 2025 | UK£1.7b | UK£304.3m | -UK£163,156,254.00 | 9.4x | -10.6x | 5.7x |
| Wed, 03 Sep 2025 | UK£1.8b | UK£291.9m | -UK£160,968,352.00 | 6.5x | -11.1x | 6.1x |
| Fri, 01 Aug 2025 | UK£2.2b | UK£291.9m | -UK£160,968,352.00 | 6.5x | -13.6x | 7.5x |
| Sun, 29 Jun 2025 | UK£1.5b | UK£291.6m | -UK£159,942,352.00 | 7x | -9.5x | 5.2x |
| Tue, 27 May 2025 | UK£1.7b | UK£319.3m | -UK£190,709,403.70 | 10.9x | -8.7x | 5.2x |
| Thu, 24 Apr 2025 | UK£1.6b | UK£315.0m | -UK£185,693,611.00 | 6.4x | -8.7x | 5.1x |
| Sat, 22 Mar 2025 | UK£1.6b | UK£315.6m | -UK£186,234,564.20 | 6x | -8.5x | 5x |
| Mon, 17 Feb 2025 | UK£1.9b | UK£306.5m | -UK£195,236,961.36 | 7x | -9.6x | 6.1x |
| Wed, 15 Jan 2025 | UK£2.0b | UK£307.7m | -UK£196,171,457.76 | 6.8x | -10.4x | 6.6x |
| Fri, 13 Dec 2024 | UK£2.1b | UK£306.2m | -UK£194,956,076.40 | 8.6x | -10.9x | 6.9x |
| Sun, 10 Nov 2024 | UK£1.9b | UK£304.9m | -UK£192,889,229.20 | 10.6x | -9.8x | 6.2x |
| Tue, 08 Oct 2024 | UK£2.0b | UK£304.4m | -UK£192,312,981.10 | 10.6x | -10.6x | 6.7x |
| Thu, 05 Sep 2024 | UK£2.0b | UK£293.8m | -UK£192,905,692.40 | 12.1x | -10.4x | 6.8x |
| Sat, 03 Aug 2024 | UK£1.8b | UK£295.5m | -UK£189,945,748.23 | 12.6x | -9.7x | 6.2x |
| Mon, 01 Jul 2024 | UK£1.5b | UK£296.0m | -UK£190,325,313.69 | 11.4x | -7.8x | 5x |
| Wed, 29 May 2024 | UK£1.6b | UK£295.5m | -UK£189,764,673.15 | 11.2x | -8.7x | 5.6x |
| Fri, 26 Apr 2024 | UK£1.5b | UK£317.6m | -UK£178,415,663.99 | 12.1x | -8.2x | 4.6x |
| Sun, 24 Mar 2024 | UK£1.8b | UK£296.0m | -UK£213,289,739.77 | 7353.2x | -8.6x | 6.2x |
| Tue, 20 Feb 2024 | UK£2.0b | UK£286.0m | -UK£189,379,093.03 | 6963.1x | -10.7x | 7.1x |
| Thu, 18 Jan 2024 | UK£2.9b | UK£450.3m | -UK£176,629,842.00 | 61.5x | -16.3x | 6.4x |
| Sat, 16 Dec 2023 | UK£3.1b | UK£450.1m | -UK£174,093,562.00 | 54.8x | -17.7x | 6.8x |
| Mon, 13 Nov 2023 | UK£3.0b | UK£456.4m | -UK£169,438,000.00 | 47.7x | -17.7x | 6.6x |
| Wed, 11 Oct 2023 | UK£2.9b | UK£458.4m | -UK£165,370,857.00 | 53.2x | -17.7x | 6.4x |
| Fri, 08 Sep 2023 | UK£3.1b | UK£440.4m | -UK£166,925,114.00 | 69.6x | -18.5x | 7x |
| Sun, 06 Aug 2023 | UK£3.4b | UK£476.5m | -UK£124,704,061.00 | 70.6x | -27.1x | 7.1x |
| Tue, 04 Jul 2023 | UK£2.9b | UK£476.6m | -UK£124,795,824.00 | 66.1x | -23.1x | 6.1x |
Price to Earnings Ratio
-23.1x
Current Industry PE
- Investors are pessimistic on the British Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.8x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 12% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does U.K. Clinical Research and Equipment compare with similar industries?
| GB Market | 1.14% | |
| Healthcare | 6.15% | |
| Life Sciences | 4.55% | |
| Clinical Research and Equipment | 4.55% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.24 | 6.5% +UK£73.9m | -8.5% | PS5.4x | |
| PRM Proteome Sciences | UK£0.017 | 13.6% +UK£719.0k | -43.8% | PS1.6x |